Condition
High-risk Percutaneous Coronary Intervention
Total Trials
7
Recruiting
0
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 7 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
7Total
Not Applicable (7)
Trial Status
Completed3
Active Not Recruiting2
Enrolling By Invitation1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT04477603Not ApplicableActive Not RecruitingPrimary
Impella ECP Early Feasibility Study
NCT05334784Not ApplicableEnrolling By InvitationPrimary
Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol
NCT06087575Not ApplicableCompleted
Early Feasibility Study of the Supira System in Patients Undergoing HRPCI
NCT06132568Not ApplicableCompletedPrimary
VITALYST Early Feasibility Study in High-Risk PCI Patients (VITALYST EFS)
NCT06099548Not ApplicableActive Not RecruitingPrimary
Magenta Elevate™ First-in-Human Clinical Study in High-Risk PCI Patients
NCT05727059Not ApplicableCompletedPrimary
Magenta Elevate™ EFS in High-Risk PCI Patients
NCT04321148Not ApplicableUnknown
Protect Kidney Trial
Showing all 7 trials